Commences Production at New EU-GMP Hormone Facility in Ahmedabad

Greenfield CommissionedCapex & Operations View source PDF Explain this filing

CORONA · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-0.6%Reaction day

₹1967.80

prior close

₹1997.00

announcement price

After-mkt

timing

Nifty Microcap 250market+0.2%-0.8% vs market

Pharmaceuticals peers, median of 165sector-0.0%-0.6% vs sector

On the reaction day the stock moved 0.8 pts less than Nifty Microcap 250 and 0.6 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-0.6

10m

-0.6

15m

-0.5

30m

-0.7

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-0.6+0.2-0.8-0.0-0.6

Next day

+1.9+1.0+0.8+0.0+1.8

+3.7+0.7+3.0+0.4+3.2

+1.8+0.9+0.9+0.1+1.7

+0.6+0.2+0.4-0.4+1.0

+0.9-1.8+2.8-1.2+2.1

+3.9+1.4+2.5-0.1+4.0

15d

+3.5-0.6+4.1-1.4+4.9

+7.5+1.5+6.0-1.2+8.7

+3.9+4.5-0.6+0.9+3.0

+2.7+3.1-0.3+0.0+2.7

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 165Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Corona Remedies has commenced commercial production at its new EU-GMP approved Women's Hormone manufacturing facility in Bhayla, Ahmedabad. Spread across 1 lakh sq ft, the facility has annual capacity of 194 million tablets and capsules and 1.5 million ointments and gels. The company says in-house hormone manufacturing capacity will rise by nearly 20%. The plant produces tablets, soft gel capsules, ointments, and gels using 21 CFR-compliant equipment and Quality by Design systems.

Likely market impact

Positive for growth: lifts hormone capacity by about 20%, strengthens women's healthcare and export potential, with revenue contribution to follow.